Literature DB >> 26226503

Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.

Geetha Srikrishna1,2,3, Shashank Gupta1,2,3, Kelly E Dooley1,2,4, William R Bishai1,2,3.   

Abstract

Entities:  

Keywords:  adjunctive therapy; bedaquiline; cardiotoxicity; drug-resistant tuberculosis; verapamil

Mesh：

Substances：

Year:  2015        PMID： 26226503     DOI： 10.2217/FMB.15.56

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


× No keyword cloud information.
  5 in total

Review 1.  Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis.

Authors:  Narendran Gopalan; Padmapriyadarsini Chandrasekaran; Soumya Swaminathan; Srikanth Tripathy
Journal:  AIDS Res Ther       Date:  2016-09-26       Impact factor: 2.250

2.  Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.

Authors:  Chao Chen; Susana Gardete; Robert Sander Jansen; Annanya Shetty; Thomas Dick; Kyu Y Rhee; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 3.  Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection.

Authors:  John A D'Elia; Larry A Weinrauch
Journal:  Int J Mol Sci       Date:  2018-08-21       Impact factor: 5.923

Review 4.  Critical discussion on drug efflux in Mycobacterium tuberculosis.

Authors:  Sille Remm; Jennifer C Earp; Thomas Dick; Véronique Dartois; Markus A Seeger
Journal:  FEMS Microbiol Rev       Date:  2022-02-09       Impact factor: 16.408

5.  First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.

Authors:  Marina Tadolini; Rangjung Dolma Lingtsang; Simon Tiberi; Martin Enwerem; Lia D'Ambrosio; Tsetan Dorji Sadutshang; Rosella Centis; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2016-06-10       Impact factor: 16.671
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.